Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Ophthalmology

Validation & Orientation: Understanding BVMD

At a Glance

Best Vitelliform Macular Dystrophy (BVMD), or Best Disease, is a rare, slowly progressing genetic eye condition caused by a BEST1 gene mutation. It causes a yellow buildup in the macula, but most patients maintain useful central vision for several decades.

Hearing that you have a genetic condition like Best Vitelliform Macular Dystrophy (BVMD)—often called Best Disease—can be overwhelming. It is natural to feel a sense of uncertainty when your central vision is affected. However, it is important to know that while BVMD is a lifelong condition, it is typically characterized by a slow and variable progression [1][2]. Many people with Best Disease maintain functional, “useful” vision for several decades, often well into their 50s, 60s, or beyond [3][4].

Understanding the Basics

BVMD is a rare inherited disorder, affecting approximately 1 in 10,000 people globally [1]. It is primarily an autosomal dominant condition, meaning if one parent carries the gene mutation, there is a 50% chance of passing it to each child [5].

The condition is caused by mutations in the BEST1 gene [6]. This gene provides instructions for making a protein called bestrophin-1, which lives in the Retinal Pigment Epithelium (RPE)—a critical layer of cells that supports and “feeds” your light-sensing retina [7].

The Biological “Egg Yolk”

To understand what is happening in the eye, it helps to think of the bestrophin-1 protein as a tiny gatekeeper or chloride channel [7][8]. It helps regulate the flow of salts (ions) and fluids in and out of the RPE cells.

When the BEST1 gene is mutated, these gatekeepers do not function correctly. This failure disrupts the way the RPE processes waste products from the retina [9]. Over time, a yellow, fatty substance called lipofuscin begins to build up under the macula (the part of the retina responsible for sharp, central vision) [10]. In the early stages, this buildup looks remarkably like a bright yellow egg yolk, which is why it is called a vitelliform (yolk-like) lesion [1].

BVMD vs. ARB

You may hear your doctor mention Autosomal Recessive Bestrophinopathy (ARB). While both involve the BEST1 gene, they are distinct:

  • BVMD (Best Disease): Usually involves a single, large “egg yolk” lesion in the center of the macula and is typically inherited from one parent [11][12].
  • ARB: Usually results from inheriting two mutated genes (one from each parent) and often presents with multiple, smaller deposits across the retina rather than one central “yolk” [11][13].

Lifestyle and Supplements

Many patients wonder about eye vitamins like AREDS2 or Vitamin A. Because AREDS2 was designed for age-related macular degeneration (AMD), it is not proven to help with genetic dystrophies like BVMD. Furthermore, high-dose Vitamin A can sometimes be harmful in certain genetic dystrophies. Always ask your doctor before starting any supplements. However, wearing high-quality UV-blocking sunglasses to protect your retina from sun damage is universally recommended.

Looking Forward: Your Prognosis

The most important thing to remember is that BVMD progresses slowly [1]. While the “egg yolk” lesion may eventually break down or “scramble” and lead to some thinning (atrophy) of the macula, this process takes many years [14][15].

  • Vision Maintenance: Many patients maintain good visual acuity (the ability to see fine detail) for a long time because the light-sensing cells can remain functional even when the yellow material is present [3][16].
  • Monitoring Complications: In some cases, new, leaky blood vessels can grow under the retina (a complication called choroidal neovascularization or CNV) [17]. If this happens, modern treatments are highly effective at stabilizing the vision [18].

Your medical team will use specialized tools to monitor your progress and ensure your eyes stay as healthy as possible [19][20]. For more details on the phases of this disease, continue to Symptoms & The 5 Stages.

Common questions in this guide

What causes the egg yolk appearance in Best Disease?
The yolk-like appearance is caused by a buildup of a yellow, fatty substance called lipofuscin under the macula. This happens because a mutation in the BEST1 gene prevents the retinal cells from properly clearing out waste products.
Will I completely lose my vision from BVMD?
BVMD typically progresses very slowly, and most people do not lose all their vision. While the macula may thin over time, many patients maintain functional, useful central vision well into their 50s or beyond.
Should I take AREDS2 or Vitamin A supplements for Best Disease?
AREDS2 was designed specifically for age-related macular degeneration and is not proven to help with BVMD. Additionally, high-dose Vitamin A can sometimes be harmful in genetic eye dystrophies, so you should always ask your doctor before starting any supplements.
What is the difference between BVMD and ARB?
BVMD usually involves a single large lesion and is inherited from just one parent. ARB requires inheriting mutated genes from both parents and often causes multiple smaller deposits across the retina instead of a single central yolk.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my imaging, what stage of BVMD am I currently in?
  2. 2.Has the specific mutation in my BEST1 gene been identified, and does it help predict the speed of my disease progression?
  3. 3.Should I be taking any specific precautions regarding supplements or high-dose Vitamin A?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Best Vitelliform Macular Dystrophy.

    Tsang SH, Sharma T

    Advances in experimental medicine and biology 2018; (1085()):79-90 doi:10.1007/978-3-319-95046-4_16.

    PMID: 30578489
  2. 2

    Best Vitelliform Macular Dystrophy Natural History Study Report 1: Clinical Features and Genetic Findings.

    Laich Y, Georgiou M, Fujinami K, et al.

    Ophthalmology 2024; (131(7)):845-854 doi:10.1016/j.ophtha.2024.01.027.

    PMID: 38278445
  3. 3

    Optical Coherence Tomography Examination of the Retinal Pigment Epithelium in Best Vitelliform Macular Dystrophy.

    Qian CX, Charran D, Strong CR, et al.

    Ophthalmology 2017; (124(4)):456-463 doi:10.1016/j.ophtha.2016.11.022.

    PMID: 28187978
  4. 4

    Photoreceptor Function and Structure in Autosomal Dominant Vitelliform Macular Dystrophy Caused by BEST1 Mutations.

    Cideciyan AV, Jacobson SG, Swider M, et al.

    Investigative ophthalmology & visual science 2022; (63(13)):12 doi:10.1167/iovs.63.13.12.

    PMID: 36512348
  5. 5

    NOVEL BEST1 MUTATIONS DETECTED BY NEXT-GENERATION SEQUENCING IN A CHINESE POPULATION WITH VITELLIFORM MACULAR DYSTROPHY.

    Guo J, Gao F, Tang W, et al.

    Retina (Philadelphia, Pa.) 2019; (39(8)):1613-1622 doi:10.1097/IAE.0000000000002183.

    PMID: 29781975
  6. 6

    Multimodal imaging and genetic characteristics of autosomal recessive bestrophinopathy.

    Tekin K, Dulger SC, Horozoglu Ceran T, et al.

    Journal francais d'ophtalmologie 2024; (47(6)):104097 doi:10.1016/j.jfo.2024.104097.

    PMID: 38518704
  7. 7

    First Pediatric Case of Autosomal Recessive Homozygotic Bestrophinopathy due to Homozygous Mutation c.187G>C p. in Two Brothers.

    Bittmann S, Luchter E, Villalon G, et al.

    Journal of clinical medicine research 2022; (14(4)):174-176 doi:10.14740/jocmr4709.

    PMID: 35573931
  8. 8

    The pentameric chloride channel BEST1 is activated by extracellular GABA.

    Pant S, Tam SW, Long SB

    Proceedings of the National Academy of Sciences of the United States of America 2025; (122(16)):e2424474122 doi:10.1073/pnas.2424474122.

    PMID: 40249777
  9. 9

    Contribution of Ion Channels in Calcium Signaling Regulating Phagocytosis: MaxiK, Cav1.3 and Bestrophin-1.

    Strauß O, Reichhart N, Gomez NM, Müller C

    Advances in experimental medicine and biology 2016; (854()):739-44 doi:10.1007/978-3-319-17121-0_98.

    PMID: 26427483
  10. 10

    Inhibition of Ca2+ channel surface expression by mutant bestrophin-1 in RPE cells.

    Cordes M, Bucichowski P, Alfaar AS, et al.

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2020; (34(3)):4055-4071 doi:10.1096/fj.201901202RR.

    PMID: 31930599
  11. 11

    Phenotype and genetic spectrum of six Indian patients with bestrophinopathy.

    Shakeel A, Bhatt DM, Gopal L, et al.

    Taiwan journal of ophthalmology 2024; (14(4)):602-608 doi:10.4103/tjo.TJO-D-24-00080.

    PMID: 39803400
  12. 12

    Association of Clinical and Genetic Heterogeneity With BEST1 Sequence Variations.

    Shah M, Broadgate S, Shanks M, et al.

    JAMA ophthalmology 2020; (138(5)):544-551 doi:10.1001/jamaophthalmol.2020.0666.

    PMID: 32239196
  13. 13

    Clinical and Genetic Features of Autosomal Recessive Bestrophinopathy: A Case Series from a Vietnamese Cohort.

    Nguyen TTT, Tran VK, Nguyen NL, et al.

    Biomedicines 2025; (13(7)) doi:10.3390/biomedicines13071625.

    PMID: 40722697
  14. 14

    Optical coherence tomography in Best vitelliform macular dystrophy.

    Battaglia Parodi M, Iacono P, Romano F, et al.

    European journal of ophthalmology 2017; (27(2)):201-204 doi:10.5301/ejo.5000878.

    PMID: 28233888
  15. 15

    Stage-dependent choriocapillaris impairment in Best vitelliform macular dystrophy characterized by optical coherence tomography angiography.

    Jauregui R, Parmann R, Nuzbrokh Y, et al.

    Scientific reports 2021; (11(1)):14300 doi:10.1038/s41598-021-93316-3.

    PMID: 34253754
  16. 16

    SHORT-TERM MODIFICATIONS OF ELLIPSOID ZONE IN BEST VITELLIFORM MACULAR DYSTROPHY.

    Romano F, Arrigo A, Leone PP, et al.

    Retina (Philadelphia, Pa.) 2021; (41(5)):1010-1017 doi:10.1097/IAE.0000000000002977.

    PMID: 32925562
  17. 17

    Choroidal Neovascularization Is Common in Best Vitelliform Macular Dystrophy and Plays a Role in Vitelliform Lesion Evolution.

    Han IC, Coussa RG, Mansoor M, et al.

    Ophthalmology. Retina 2023; (7(5)):441-449 doi:10.1016/j.oret.2022.11.014.

    PMID: 36528270
  18. 18

    Intravitreal bevacizumab treatment for exudative choroidal neovascularisation in best vitelliform macular dystrophy.

    Jarc-Vidmar M, Sega R, Jaki-Mekjavic P

    European journal of ophthalmology 2021; 11206721211057684 doi:10.1177/11206721211057684.

    PMID: 34779297
  19. 19

    Multimodal imaging in Best Vitelliform Macular Dystrophy: Literature review and novel insights.

    Bianco L, Arrigo A, Antropoli A, et al.

    European journal of ophthalmology 2024; (34(1)):39-51 doi:10.1177/11206721231166434.

    PMID: 36972471
  20. 20

    [Optical coherence tomography and fundus autofluorescence in Best macular dystrophy].

    Chebil A, Charfi H, Largueche L, El Matri L

    Journal francais d'ophtalmologie 2016; (39(6)):543-8.

    PMID: 27206620

This page explains Best Vitelliform Macular Dystrophy (BVMD) for educational purposes only. Always consult your ophthalmologist or genetic counselor for guidance tailored to your specific vision health and progression.

Get notified when new evidence is published on Best vitelliform macular dystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.